Related Experiment Video

Updated: Jun 5, 2026

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model

I Cetin1, B Huppertz, G Burton

  • 1Unit of Obstetrics and Gynaecology, Department of Clinical Sciences, L. Sacco and Centre for Fetal Research Giorgio Pardi, University of Milan, 20157 Milano, Italy. irene.cetin@unimi.it

Placenta
|December 28, 2010
PubMed

Insights

This consensus meeting focused on early markers for preeclampsia (pregnancy-induced hypertension). Key research priorities include single vs. multiple markers and long-term health effects for cost-effective screening.

Area of Science:

  • Obstetrics and Gynecology
  • Maternal-Fetal Medicine
  • Clinical Biochemistry

Background:

  • Preeclampsia poses significant risks to maternal and perinatal health.
  • Current knowledge on early preeclampsia markers requires critical review and synthesis.
  • The need for effective prediction and early screening strategies is paramount.

Framework:

  • The Pregenesys Consortium convened a consensus meeting on July 13, 2009, in Cambridge.
  • The meeting aimed to critically discuss existing knowledge on early preeclampsia markers.
  • Key objectives included identifying research priorities and future recommendations.

Implementation:

  • Discussion focused on single versus multiple marker strategies for risk identification.
  • Consideration was given to early versus late risk identification timeframes.
  • The meeting addressed cost-effectiveness and national policy implications for screening.

Implications:

  • Future research should prioritize specific marker combinations and risk identification timing.
  • Long-term maternal and perinatal health outcomes must be integrated into cost-benefit assessments.
  • The findings will inform future recommendations for preeclampsia prediction and screening policies.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...